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ABSTRACT 
IS MACROLIDE AND BETA-LACTAM COMBINATION THERAPY ASSOCIATED 
WITH IMPROVEMENT IN HOSPITALIZED PATIENTS WITH PNEUMONIA? AN 
ASSESSMENT OF CONFOUNDING BY INDICATION 
Evangeline Pierce 
October 31, 2018
 Pneumonia and influenza are one of the leading causes of infectious 
disease-related deaths worldwide. Current guidelines for the treatment of 
hospitalized patients with community acquired pneumonia (CAP) include empiric 
antimicrobial therapy with a macrolide and a beta-lactam. There is little 
consensus among studies as to which antimicrobial regimen is best.  The 
confusing results seen may very well be due to lack of assessment of 
confounding by indication (CBI). This analysis was a secondary analysis from 
Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study (HAPPI). 
The study participants were those in HAPPI who had received either macrolide 
and beta-lactam combination therapy or fluoroquinolone mono-therapy within the 
first 24 hours (n= 3141). The outcomes studied were early clinical stability (ECS) 
and 30 day mortality. No statistically significant association was found between 
macrolide and beta-lactam use and ECS using any of the methods used for 
addressing confounding by indication, logistic regression, propensity score 
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matching, or instrumental variable analysis (Odds Ratio (OR): 0.908, 95% 
Confidence Interval (CI): 0.780, 1.059; OR: 0.916, 95% CI:0.775, 1.083; OR: 
1.551, 95% CI: 0.777, 3.091, respectively). The two methods addressing 
measured confounding (logistic regression and propensity score matching) had 
similar OR’s while the method addressing unmeasured confounding (instrumental 
variable analysis) had a contradictory OR, even though the results were all non 
significant. No statistically significant association was found between macrolide 
and beta-lactam use and 30 day mortality using logistic regression, propensity 
score matching, or instrumental variable analysis (OR: 0.926, 95% CI: 0.692, 
1.241; OR: 0.885, 95% CI: 0.748, 1.048; OR: 0.958, 95% CI: 0.603, 1.523, 
respectively). All three methods looking at combination therapy and 30 day 
mortality were in agreement. When addressing confounding and CBI more than 
one method for analysis should be used.  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LITERATURE REVIEW 
1.1.1 Introduction  
 The purpose of this dissertation is to determine the efficacy of macrolide 
and beta-lactam combination therapy versus fluoroquinolone mono-therapy in the 
treatment of community acquired pneumonia (CAP) through the assessment of 
early clinical stability (ECS) and 30 day mortality through the comparison of three 
different statistical approaches to controlling for confounding by indication. Data 
was extracted from the Hospitalized Adults with Pneumococcal Pneumonia: 
Incidence Study (HAPPI). Currently, there is a lack of consensus among 
epidemiological studies as to which antimicrobial regiment is best, due to 
variation in the variables  included and lack of using more than one statistical 
method to address confounders and thus confounding by indication. There are 
two specific aims for this dissertation. The first is to evaluate three years of study 
data and determine whether macrolide and beta-lactam combination therapy 
usage is appropriate for gold standard treatment in hospitalized community 
acquired pneumonia though assessment of ECS and 30 day mortality. The 
second aim is to assess and compare various methods addressing CBI 
(multivariable logistic regression, propensity score stratification and matching, 
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instrumental variable analysis) through the assessment of macrolide and beta-
lactam combination therapy and its effect on ECS and 30 day mortality in 
hospitalized patients with community acquired pneumonia. 
  
1.1.2 Community Acquired Pneumonia 
 Together, pneumonia and influenza are leading causes of infectious 
disease related deaths worldwide and the eighth leading cause of death in the 
United States (1, 2). The setting in which pneumonia develops is important as it 
determines the type of pneumonia: CAP, healthcare associated pneumonia 
(HCAP), hospital-acquired pneumonia (HAP),  or ventilator-associated 
pneumonia (VAP) (3, 4). CAP is characterized by acute symptoms such as 
dyspnea, cough, fever, or chest pain, and is diagnosed by the presence of 
pulmonary infiltrate seen on radiography. It is distinguished from HAP in that the 
patient is exposed to causative pathogens in the community and not a hospital 
setting.  
 CAP is a common infectious disease with an estimated incidence of 2–11 
cases per 1000 adults in the developed world and a mortality rate of 2%–14% 
(5). It is approximated that, in the US, more than 1.5 million adults infected with 
CAP are hospitalized annually, with 100,000 deaths occurring during 
hospitalization (6, 7). Not only are the economic and clinical burdens of CAP 
high, but there are also long term effects on quality of life that need to be 
considered when looking at the overall effect of CAP (8). 
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 The risk of CAP increases with age: however those in early childhood are 
also at increased risk (9, 10). It is estimated that 1 of every 20 persons aged 85 
years or greater will have a new episode of CAP each year (10). Those with 
increased age often have at least one other medical condition which can 
complicate CAP (11). Elderly patients categorized as frail (i.e. those who need 
help with daily activities, who have severe multimorbiditiy, polypharmacy, and 
possible dementia) are at a much higher risk of CAP than those who have who 
are not frail (11, 12). However, even without comorbidities, age is an independent 
risk factor for CAP due to the decreased ability of the immune system to protect 
against pathogens, decreased ability to have a productive cough, and decreased 
swallowing reflex (13). CAP patients over 65 years of age account for about one 
third of all cases, but they are also responsible for more than half of all 
healthcare expenses (14). As the population of the US is aging, the burden of 
CAP can only be expected to increase (15). 
 Many diseases and existing health conditions that can also cause greater 
exposure or greater risk of exposure of heightened severity of CAP-causative 
pathogens. Chronic lung diseases (i.e. cystic fibrosis, chronic obstructive 
pulmonary disease (COPD), and lung cancer) that inhibit airflow can lead to 
increased risk (16). Patients with Diabetes Mellitus, human immunodeficiency 
virus (HIV), and those on immunosuppressants have increased risk of CAP due 
to a compromised immune system (17, 18). Patients taking gastric acid 
suppressants (medication that decreases the production of acid in the stomach), 
those who smoke, and those who drink alcohol are at an increased risk for CAP  
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(16, 19). A recent study also found that clusters of patients with CAP were found 
in areas with low-income and black populations (7). Unlike many respiratory 
diseases, CAP does not have seasonality (20). 
1.1.3 Community Acquired Pneumonia: Etiology 
 CAP most common results from bacterial pathogens. However viruses, 
fungi, and parasites are also known to cause CAP (21). Many causative CAP 
pathogens are associated with specific risk factors. Risk factors for gram-
negative bacilli include previous antibiotic therapy, recent hospitalization, 
immunosuppression, pulmonary comorbidity (e.g., cystic fibrosis, bronchiectasis, 
or repeated exacerbations of chronic obstructive pulmonary disease that require 
frequent glucocorticoid and/or antibiotic use), probable aspiration, and multiple 
medical comorbidities (eg, diabetes mellitus, alcoholism) (3, 22-24). Risk factors 
associated with drug-resistant microbes include age over 65 years, beta-lactam, 
macrolide, or fluoroquinolone therapy within the past three to six months, 
alcoholism, medical comorbidities, immunosuppressive illness or therapy, 
exposure to a child in a daycare center, prior hospitalization, or residence in a 
long-term care facility (25). 
 Unfortunately the actual incidence is difficult to determine due to 
contamination of samples with colonizing bacteria. S. pneumoniae has been 
found in up to 15 percent of bacterial CAP cases, but the incidence of CAP due 
to S. pneumoniae has been decreasing due to the use of pneumococcal 
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vaccines in adults, as well as the decreasing prevalence of smoking (26, 27). S. 
pneumoniae is the leading cause of pneumonia in the elderly population (28). 
Other common bacteria known to cause CAP in adults are H. influenzae often 
occurring in adults with underlying lung disease, M. pneumoniae the most 
common CAP causing atypical bacteria, C. pneumoniae which is common in 
outbreaks, Legionella which can occur sporadically or in outbreaks, and 
Klebsiella pneumoniae which is common in those that have severe underlying 
diseases such as alcoholism or diabetes  (29-33).  
 The bacterial organisms are often split into two groups, typical and 
atypical. Bacteria causing typical pneumonia include S. pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, group A streptococci, 
Moraxella catarrhalis, anaerobes, and aerobic gram-negative bacteria . Atypical 
bacteria leading to atypical pneumonia include Legionella spp, M. pneumoniae, 
C. pneumoniae, and Chlamydia psittaci.  
 The incidence of viral CAP depends on the diagnostic method used to 
determine cause (34). The most common and significant virus is Influenza. 
Infection with Influenza A or B can not only cause CAP, but it can also predispose 
a patient to a superimposed bacterial infection which is causative for CAP (35). 
Parainfluenza and respiratory syncytial virus (RSV) are seen more often in 
immunocompromised adults; however, RSV can cause respiratory tract illnesses 
in all age groups (36-38). Other viruses that have been found in patients with 
CAP are rhinovirus, coronavirus, and human metapneumovirus. However, it is 
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possible these viruses are not causative for CAP but simply predispose a person 
to a bacterial co-infection (35).  
 Fungi are not a common cause of CAP, but they can cause CAP in both 
immunocompetent and immunocompromised patients who live in or have visited 
specific endemic areas. Coccidioides fungi are endemic to desert areas including 
southern Arizona, central California, southwestern New Mexico, and west Texas, 
and they have been found to cause CAP in patients from this area (39, 40). H. 
capsulatum is most common in the Midwestern United States located in the Ohio 
and Mississippi River Valleys; however the development of symptomatic disease 
depends on the level of exposure (41, 42). 
 Determining the pathogenicity of CAP often depends on the severity of 
CAP and the location of treatment, whether in the outpatient or inpatient setting 
(3, 43). Many cases of CAP are never tested for a pathogen or have no pathogen 
identified (30, 43).  Traditionally, physicians consider lobar consolidation to be 
due to the "typical" bacteria and interstitial infiltrates to be a result of 
Pneumocystis jirovecii (formerly P. carinii) and viruses. Nevertheless, it has been 
shown that radiologists cannot reliably differentiate bacterial from nonbacterial 
pneumonia on the basis of a radiographic image (44, 45). Recently a review of 
Medicare patients hospitalized for CAP in 2009 showed a microbial diagnosis 
was made in less than 10% of cases (46). Blood cultures, sputum Gram stain 
and cultures, and urine antigen tests are recommended in hospitalized patients 
to determine the microbial diagnosis (3, 47).  
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 Blood cultures are positive for a pathogen in only 7 to 16 percent of 
hospitalized patients with S. pneumoniae accounting for two-thirds of the positive 
results (48, 49). There is a high rate of false positives with blood cultures (10%) 
and in clinical practice a positive culture rarely leads to changes in antibiotic 
therapy (48, 50).  
 Expectorated sputum can be used for testing via a Gram stain and culture, 
though expectorated sputum can lead to contamination with upper airway flora. 
Therefore other methods can be used such as transtracheal aspiration, 
transthoracic aspiration, and the collection of specimens at bronchoscopy (46). 
The sensitivity and specificity of the sputum Gram stain can vary in different 
settings, with a meta analysis showing sensitivity of Gram stain compared with 
culture ranging from 15 to 100 percent and specificity ranging from 11 to 100 
percent (51). This variation is most likely from using different thresholds for a 
positive test. Guidelines recommend that expectorated sputum Gram stain and 
culture be done only if a good-quality sputum can be obtained (3).  
 Urinary antigen assays are typically used to detect S. pneumoniae and 
Legionella. In a prospective study, the sensitivity of the pneumococcal urinary 
antigen was 71 percent and the specificity was 96 percent. Interestingly the 
results of the urinary antigen test led the clinicians in the study to reduce the 
spectrum of antibiotics in nine percent of patients with CAP (52). It is 
recommended that the pneumococcal urinary antigen assay be used to augment 
the standard diagnostic methods of blood culture and sputum Gram stain and 
culture (53). A new test that has been approved by the US Food and Drug 
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Administration (FDA) is a polymerase chain reaction (PCR) for detecting C. 
pneumoniae, M. pneumoniae, and 14 respiratory tract viruses, and these tests 
are rapid, sensitive, and specific (54).  
1.1.4 Community Acquired Pneumonia: Severity 
 CAP can be treated inpatient or outpatient. Severity of illness is the 
strongest factor in the determination of location of treatment, but other factors 
may taken into account, such as ability to maintain oral intake of fluids and 
medications, likelihood of medication adherence, history of active substance 
abuse, mental illness, cognitive or functional impairment, and living or social 
circumstances (55). 
 The severity of CAP is oftentimes determined through the Pneumonia 
Severity Index (PSI) (56). This score is used to predict the need for 
hospitalization for a patient. PSI ranges from I to V, with a higher score indicating 
much more severe CAP. The score includes demographic information, 
comorbidities, initial physical exam results, lab results, and radiographical results 
(56). PSI scores have low sensitivity and specificity for intensive care unit (ICU) 
admission, and they do not account for other variables affecting severity such as 
psychosocial variables, non-common comorbidities, or patient preferences 
regarding treatment (11).  
 Another method to determine CAP severity is through CURB-65 scoring 
(Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and 
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older) (57). CURB-65 scores, ranging from 0 to 5 with the severity of CAP 
increasing with the score, are easier than the PSI to calculate and interpret as 
CURB-65 includes only five variables compared to the possible 20 in the PSI. 
The CRB-65 score provides a four-variable substitute for use where blood testing 
is not available. The CURB-65 scores do not include data such as hypoxemia, 
electrolyte disturbance or the inability to take oral medications which could 
indicate greater severity of CAP (11).  
 Guidelines are not consistent in the recommendation of which score to 
use for the determination of severity. The American Academy of Family 
Physicians (AAFP) guidelines recommend outpatient treatment for PSI risk 
classes I and II and hospitalization for those in risk classes IV and V. The location 
of treatment for class III is left to clinical judgement (55, 58). The Infectious 
Diseases Society of America (IDSA) guideline recommends that physicians 
consider outpatient treatment for patients in PSI risk classes I, II and III, and 
hospitalization for those in classes IV and V (3). The British Thoracic Society 
(BTS) recommends that physicians use the CURB-65 or the CRB-65 when 
deciding on hospitalization or outpatient treatment, with scores 0-1 being 
recommended for outpatient treatment and 2-5 recommended for hospitalization. 
(59). The American Thoracic Society (ATS) guidelines recommend that clinicians 
use clinical decision scores like the PSI or CURB-65 to support clinical judgment, 
but the do not define a recommended cutoff for hospital admission (60). Most 
importantly all of the guidelines recommend that clinicians use PSI and CURB-65 
scoring tools to support, not replace, clinical judgment. 
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1.1.5.1 Community Acquired Pneumonia: Treatment 
 Treatment recommendations depend on the type of care a patient 
requires. Once a patient meets the symptom requirements of CAP the necessary 
level of care is decided. More severe cases will lead to an inpatient setting, which 
occurs on medical wards or the ICU. Effective empirical treatment involves the 
selection of an antimicrobial agent with a spectrum of activity that includes the 
causative pathogen. Often, the causative organism takes a while to be confirmed 
or is unable to be determined. Therefore empiric antimicrobial therapy is 
encouraged to begin as soon as possible beginning with a broad-spectrum 
antimicrobial agent before de-escalating to narrow-spectrum agents dependent 
on the identification of a pathogen (3, 59, 61-63). It is recommend that 
antimicrobials be administered as soon as possible after diagnosis of CAP and 
before leaving the emergency department, especially in those over 65 years of 
age (3, 64, 65). Patients with sepsis or septic shock should have antibiotics 
started within one hour.
1.1.5.2 Community Acquired Pneumonia Treatment: Macrolides 
 Macrolide antimicrobials are used to treat gram-positive bacteria, such as 
S. pneumoniae, and some gram-negative bacteria like H. influenzae. Macrolides 
inhibit protein synthesis in bacteria by binding to the 50S ribosomal subunit and 
preventing polypeptide elongation and thus protein synthesis  (66, 67). 
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 Macrolides also appear to decrease the production of pro-inflammatory 
cytokines, thereby decreasing inflammation in patients (68, 69). A study 
assessed the affects of macrolides on the human immune system, ex vivo, using 
healthy volunteers (70). It was found that there was a neutrophil degranulating 
effect of azithromycin (a type of macrolide), which was seen in rapid decreases in 
azurophilic granule enzyme activity in the cells, with corresponding increases in 
the serum. The oxidative burst response to a particulate stimulus was also 
enhanced. Both of these inflammatory responses occurred when serum and 
neutrophil azithromycin concentrations were higher, peaking at the 24-hour mark 
and then gradually decreasing over the next 27 days. In addition, decreases in 
chemokines (IL-8 and human growth related oncogene-a) and IL-6 serum 
concentrations accompanied a down-regulation of the oxidative burst and an 
increase in neutrophil apoptosis for up to 28 days after. The fact that these anti-
inflammatory effects begin to occur so quickly after the start of a treatment 
regimen could, in theory, correlate with the improved outcomes noted in some 
CAP patients (69). It has also been suggested that macrolides can assist in the 
stabilization of the epithelial membrane which contributes to decreased an 
inflammation (67). 
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1.1.5.3 Community Acquired Pneumonia Treatment: Beta-Lactam and Macrolides
 Beta-lactams are antimicrobials that are effective against gram-positive 
bacteria and some gram-negative bacteria. They act by inhibiting the synthesis of 
bacterial walls (71). 
 In hospitalized patients with CAP empiric therapy with both a macrolide 
and a beta-lactam is the preferred treatment according to the IDSA (3). Although 
the mechanism of action is not well understood, it has been suggested that the 
combination of a macrolide and a beta-lactam can lead to improved clinical 
outcomes, including lower mortality (72, 73). 
1.1.5.5 Community Acquired Pneumonia Treatment: Fluoroquinolone
 Fluoroquinolones are direct inhibitors of bacterial DNA synthesis and bind 
to the complex of specific enzymes within DNA, thus inhibiting progress of the 
DNA replication, leading to bacterial DNA and cell death (74). Fluoroquinolones 
work best against aerobic gram-negative bacilli (75). They are contraindicated if a 
patient has significant QT prolongation, pre-existing CNS lesions or CNS 
inflammation, or has suffered a stroke (76). Because of the severity of adverse 
effects and the increased risk for C. difficile infection, combination therapy with a 
beta-lactam plus a macrolide is recommended over mono-therapy with a 
fluoroquinolone (3, 77). However, fluoroquinolones are an option for treating 
atypical bacterial pneumonia (3). 
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1.1.5.6 Community Acquired Pneumonia Treatment: Other Treatments
 Antiviral therapy for non-influenza pneumonia has typically been evaluated 
in immunosuppressed patients and infants. There has been minimal research 
looking at the use of antivirals for other populations (78-82). Fungal CAP is 
typically treated with an antifungal like Amphotericin B (or its derivatives) and 
itraconazole (83).  
1.1.5.7 Community Acquired Pneumonia Treatment: Recommendations  
The current recommended first line antimicrobial treatment includes a 
macrolide plus a beta-lactam (3). Respiratory fluoroquinolones are used in 
patients who cannot take a macrolide or a beta-lactam (84). Strains of drug 
resistant S. pneumoniae bring the current recommendations into question (85).
 Even though the guidelines are widely accepted, there is disagreement on 
the utility of macrolides in the treatment of CAP. The majority of the studies used 
by the IDSA and the ATS were retrospective cohort studies (3). However, other 
retrospective studies and some randomized control trials have given evidence to 
question the benefits of macrolide as they suggest the use of beta-lactam mono-
therapy for patients hospitalized with mild CAP (86-93). 
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1.1.6 Community Acquired Pneumonia: Clinical Outcomes 
 One way to measure how a patient with CAP is improving in the hospital is 
to assess clinical stability. In a recent Federal Drug Administration (FDA) paper, 
emphasis was placed on symptom resolution as objective evidence of clinical 
improvement in patients with CAP (94).  The FDA has also advocated for clinical 
stability to be an important endpoint in clinical trials comparing different treatment 
regimens (95). It has been found that the rate of mortality or readmission among 
patients who had CAP was about 10% when a patient satisfied all conditions of 
clinical stability (96). 
 The ATS has a defined set of criteria and guidelines as to what qualifies as 
clinically stable (97). These criteria include improved symptoms of pneumonia 
(cough and shortness of breath), lack of fever for at least eight hours, and 
improving leukocytosis (white blood count decreased at least 10% from the 
previous day). All of the ATS criteria should be present during the same day 
compared to the previous day to define clinical stability. The IDSA has another 
set of criteria for clinical stability (97). The criteria is listed as follows: temperature 
</= 37.8 C, heart rate </= 100 beats per minute, respiratory rate </= 24 breaths 
per minute, systolic blood pressure >/= 90 mmHg, arterial oxygen saturation >/= 
90% or a partial pressure of oxygen >/= 60 mmHg on room air, and normal 
mental status. The IDSA criteria should all be present on the same day to qualify 
as clinically stable. Although the two set of criteria vary, it has been shown that 
they are clinically equivalent and either can be used for research or clinical 
practice (97).  
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 ECS occurs when the criteria are met on or before the third day of 
hospitalization (98). ECS at day three was traditionally based on older studies 
suggesting that clinical differences in patients treated with antibiotics are 
apparent earlier than day three of antibiotic treatment. This same time frame is 
also relevant because the results of the many pathogen tests are usually 
available within three days (98-100). 
 Other outcomes typically studied with respect to CAP include in-hospital 
mortality, 30-day mortality, long-term mortality, and readmission for CAP (3, 56, 
101-105). Readmission to the hospital after discharge is typically used as an 
indicator of vulnerability (106).  
1.2.1 Community Acquired Pneumonia and Confounding by Indication 
 The pathogens and management of CAP have been well studied and 
many of these studies have assessed antibiotic use for patients with CAP. 
However these results can be brought into question when assessing for 
confounding by indication (CBI) (87, 89, 107-115). 
 Confounding is present when a variable influences both the independent 
variable (e.g. an antibiotic treatment) and the dependent variable (e.g. a clinical 
outcome) (116).  Confounding by indication (CBI) is a type of confounding that 
occurs when a treatment (the primary predictor variable) is selected due to a 
specific characteristic (e.g. history of a particular disease, provider medication 
preference) and this characteristic also affects the risk of the outcome variable 
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(117, 118). Not correctly addressing confounding can lead to biased and 
inaccurate statistical results (117, 119).  
1.2.3 Meta Analyses Assessing Antibiotic Usage in Community Acquired 
Pneumonia 
 Meta-analyses have been performed to assess the effect of macrolide 
therapy (both combination and mono therapy) on mortality associated with CAP, 
Table 1 (88, 120).  
 Asadi et al, 2012, assessed macrolide based regimens (macrolide mono-
therapy, macrolide + beta lactam combination therapy, and fluoroquinolone 
therapy) and mortality in hospitalized patients with CAP (88). They included both 
randomized control trials and observational studies in their analysis, for a total of 
23 studies, 18 observational cohorts and 5 randomized control trials. They found 
macrolide use was associated with a statistically significant lower risk of mortality 
compared with non-macrolide use (RR, 0.78; 95% CI, 0.64–0.95; P = .01). There 
was a significant amount of heterogeneity among the studies (I2 = 85%) that was 
not explained, though it could have been due to confounding by indication that 
was not addressed equally across studies (i.e. it was noted that confounders 
were not consistent throughout studies). Heterogeneity could have also resulted 
from study design differences (e.g. low sample size, differences in inclusion or 
exclusion criteria, etc.). This seems to be supported when one looks at the 
effects of macrolide usage on mortality in only the randomized control trials 
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(comparing macrolide-based regimens and fluoroquinolone treatment, RR, 1.13; 
95% CI, 0.65–1.98; P = .66), where the heterogeneity was low (I2 = 0%). The 
analysis also found that there was no significant difference of mortality comparing 
macrolide and beta-lactam combinations and fluoroquinolone use (RR, 1.17; 
95% CI, 0.91–1.50; P = .22; I2 = 43%). They concluded that treatment with a 
macrolide regiment has a reduction in mortality compared to non-macrolide 
treatments. However, no difference in mortality between macrolide and beta-
lactam combination therapy and fluoroquinolone mono-therapy (both guideline 
concordant treatments) was seen.  
 Vardakas et al, 2017, assessed mono-therapy (macrolides, beta-lactams, 
and fluoroquinolones) and combination therapy (macrolide + beta-lactam, 
fluoroquinolone + beta-lactam) in community-acquired pneumonia (120). Mono-
therapy regimens were not associated with higher mortality when compared with 
combination therapies (RR 1.14, 95% CI 0.99-1.32, I2 84%). As seen with Asadi 
et al, 2012, heterogeneity was lower or non existent in analyses of randomized 
control trials.They propose that the percentage of patients with heart disease, 
cancer and severe pneumonia could partly account for the observed 
heterogeneity, but data for potential confounding factors were not consistently 
reported across studies. Interestingly, macrolide mono-therapy was associated 
with lower mortality than macrolide and beta-lactam combination therapy (0.68, 
0.51-0.92, I2 32%), even after removing the two largest studies (0.59, 0.35-1.00, 
I2 34%). The authors note that the lower mortality seen with macrolide mono-
therapy seems to contradict the increasing prevalence of resistance to macrolide 
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antibiotics, unless there is an assumption that confounding by indication is 
occurring, as seen in several of the included studies where macrolide mono-
therapy was administered in younger patients and those at a lower risk for death. 
The authors conclude that this analysis of studies is not conclusive due to the 
heterogeneity and lack of adjustment for confounding factors. 
1.2.4 Randomized Control Trials Assessing Antibiotic Usage in Community 
Acquired Pneumonia 
 Randomized control trials are considered the gold standard when 
evaluating the efficacy of treatments in clinical research. The randomization 
inherent in this type of study means that when there are observed differences 
between the treatment types with respect to a particular outcome variable, these 
differences are due solely to the treatment and not to other variables (e.g. age, 
Table 1. Macrolide and CAP Meta Analyses
Study Studies Assessed Therapies Assessed Results
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therapy and beta-lactam + 
macrolide combination
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sex, other medications) (121). Randomized control trials also have minimal bias 
and confounding variables (121). However, not only are randomized control trials 
expensive, but they are sometimes unethical. As many patients hospitalized with 
CAP are in critical condition, getting informed consent so the patient can 
participate in a trial is sometimes impossible (i.e. the medication must be 
administered immediately and patients are unable to consent). 
 Even with the complications that come with a randomized control trial, 
there have been trials assessing the effectiveness of the recommended 
macrolide and beta-lactam combination therapy against mono-therapy of non-
macrolide regimens, Table 3.  
 Garin et al, 2014, assessed the guideline treatment of macrolide and beta-
lactam combination therapy against beta-lactam mono-therapy in a randomized 
non-inferiority trial, which tests whether the treatment being evaluated is equally 
as effective as the standard treatment (90). This was an open-label, multicenter, 
non-inferiority, randomized trial in immunocompetent patients hospitalized with 
CAP in Switzerland. Patients were treated with a beta-lactam and a macrolide 
combination therapy or with beta-lactam mono-therapy. It was found after 7 days 
of treatment, 41.2% of patients receiving combination therapy had not reached 
clinical stability, compared to only 33.6% of patients receiving mono-therapy 
(P=0.07). Interestingly, those who were known to have atypical pathogens or had 
more severe pneumonia (PSI IV) were less likely to reach clinical stability at 7 
days with the beta-lactam mono-therapy (HR, 0.99; 95% CI, 0.80-1.22). There 
were more 30-day readmissions with beta-lactam mono-therapy (7.9%, P = .01). 
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Additionally, there was no difference between combination therapy and mono-
therapy with respect to mortality, intensive care unit admission, complications, 
length of stay, and recurrence of pneumonia within 90 days.  
 Postma et al, 2015, did a cluster-randomized, crossover trial assessing 
patient outcomes in patients in the Netherlands who received guideline 
concordant treatment, beta-lactam and macrolide combination therapy or 
fluoroquinolone mono-therapy,  and beta-lactam mono-therapy (122). In the 
intention-to-treat analysis, the risk of death was higher by 1.9% (90% CI, -0.6 to 
4.4) with the beta-lactam and macrolide combination therapy when compared to 
the beta-lactam mono-therapy. The risk of death was lower by 0.6% (90% CI, 
-2.8 to 1.9) with fluoroquinolone mono-therapy than with beta-lactam mono-
therapy. The study concluded that in patients with clinically suspected CAP 
admitted to non-ICU wards, beta-lactam mono-therapy was non-inferior to beta-
lactam and macrolide combination therapy or fluoroquinolone mono-therapy with 
regard to 90-day mortality. 
 Figueiredo-Mell et al, 2018 assessed the effects of beta-lactam mono-
therapy versus beta-lactam and macrolide combination therapy in patients with 
HIV and CAP (123). Based in Brazil, patients were given either a beta-lactam 
and a placebo or a beta-lactam and a macrolide. There was no difference found 
for in-patient mortality or 14-day mortality between the two groups, Hazard Ratio 
(HR) 1.22, 95% CI 0.57-2.59 and RR 2.38, 95% CI 0.87-6.53, respectively.  
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 The results of these randomized trials bring into question the current 
guideline recommendation of macrolide combination therapy (3).  
1.2.5 Individual Studies Assessing Antibiotic Usage in Community Acquired 
Pneumonia 
 Table 2 is an overview of many of the studies that have assessed 
variations of antibiotic therapy and their effect on CAP (86, 87, 89, 109-114).  
These studies were selected based on study location (in the United States) and 
population age (non-pediatric). Some of these studies adjusted for CBI though 
multivariable logistic regression, but those studies did not have a consensus on 
the appropriate therapy for CAP (110, 112-114). Of note, logistic regression does 
Table 2. Randomized Control Trials and CAP Therapy
Study Study Type Therapies Assessed Results
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not entirely control for CBI as many times the effects of the variables used are 
often not truly independent of other individuals variables (124). Only one study 
used a secondary method to control for CBI through propensity score analysis. 
No difference in 30-day mortality in either beta-lactam and fluoroquinolone or 
beta-lactam and macrolide combination therapies was found (89). Note that there 
was no consensus between these studies regarding the effect of macrolide 
usage on CAP, and the lack of overall assessment or attention to CBI brings 
many of their conclusions into question. 
Table 3. Macrolide Studies Assessing Confounding By Indication (CBI)
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Table 3 continued. Macrolide Studies Assessing Confounding By Indication (CBI)
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1.3.1 Confounding By Indication 
 In an observational study, there is a predictor variable, which is the main 
variable of interest in the study, and an outcome variable, the endpoint of interest 
in a study. Confounding can appear to strengthen, weaken, or change the effect 
of a primary predictor variable and the outcome (Figure 1). 
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 Three criteria must be met for a variable to be considered a confounder 
(125, 126). One, a confounder must be an independent risk factor for the 
outcome. Two, a confounder must be associated with the exposure. Three, a 
confounder cannot be an intermediate variable between the exposure and the 
outcome. Confounding variables can be measured or unmeasured (Figure 2). 
Table 3 continued. Macrolide Studies Assessing Confounding By Indication (CBI)










No Compared with beta-
lactam mono-therapy, 
combination macrolide 
plus additional antibiotic 
therapy effectively 
lowered the case-fatality 
rate among ill adults ⩾50 
years of age.
Figure 1. Diagram of Confounding
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  CBI occurs when a specific treatment (primary predictor variable) is 
selected for a particular characteristic and this characteristic also affects the risk 
of the outcome variable. CBI is based on confounding bias, which can be 
described as the differential distribution of a third factor between study groups 
(127). For example, an investigator may be looking at the effect of anti-
depressants in pregnancy and its affect on the development of autism. 
Depression would be a variable leading to CBI as it would indicate the need for 
the treatment (via antidepressants) and it can also affect the development of 
autism in a child, thereby affecting the risk of the outcome (128). 
 Due to the varying effects CBI can have between the primary predictor 
variable and the outcome variable, it is important to control for this event through 
various statistical means. Traditionally, the use of multivariable regression models 
and propensity score methods are used, but a third lesser known method, 
instrumental variable analysis is also effective in controlling for CBI (129-132). 
However no method has been shown to completely control for these CBI outside 
of true randomization, which is often unfeasible (133). 
Figure 2. Diagram of Confounding, Measured (M) and Unmeasured (U)
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1.3.2 Multivariable Regression Model 
 Multivariable regression models are common in statistical analysis of 
observational studies. Regression models are used to model the likelihood of a 
binary outcome. The actual model used should fit the data collected and should 
be able to mathematically answer the questions posed in the study.  
 Logistic regression can only control for CBI on the condition that all the 
variables in the model are measured accurately. Logistic regression is limited in 
its ability to fully adjust a model for CBI because the number of variables that 
would need to be included in the model is typically more than a study’s sample 
size would allow. Typically in a model with a binary outcome it is assumed that a 
minimum of ten patients will be needed per each predictor (or confounder) 
variable in the model, with many studies suggesting 15-20 cases per variable 
(134, 135). Missing data in any variable can affect the final sample size, so there 
should be a larger number of patients recruited than are mathematically needed. 
The multivariable regression model may also ignore complex relationships and 
may not account for interactions or for nonlinear relationships between the 
confounding variable and the outcome variable (e.g. if the health status of a 
patient affects the type of treatment being given). Regression modeling also 
cannot account for confounders that are unknown or unmeasured (136).  
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1.3.3 Propensity Scoring
 A propensity score is the probability of treatment assignment conditional 
on observed baseline characteristics (137). Propensity scores are used to 
balance confounding variables between study groups, mainly for predictor 
variables (e.g. treatment type) that are provided to a patient in a non random 
fashion (133, 137-139). Conditional on the propensity score, the distribution of 
measured baseline covariates is similar between those with the treatment of 
interest and those without the treatment (139).  
 A propensity score begins with a multivariable regression model that 
estimates the joint effects on the primary predictor variable (e.g. the treatment) 
with variables thought to be associated with the probability of receiving the 
primary predictor variable (the treatment). A propensity score is usually defined 
as the estimated probability of receiving the primary predictor variable. There is 
debate regarding which variables to include in the creation of the propensity 
score (139-141). However, it is agreed that a misspecified propensity score will 
not completely balance confounding effects (142, 143).  
 Using a simplified formula for logistic regression is the first step in 
developing a propensity score as follows: 
Primary Predictor (Treatment) = ⍺ + Variable1 + Variable2 + … Variablen 
 The variables included in the regression model will change the likelihood 
of an individual obtaining the primary predictor variable (e.g. treatment type). For 
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example, if the predictor is a medication, such as a macrolide, the variables 
included would be those that are associated with the probability of a patient being 
prescribed that particular medication (e.g. variables that affect the propensity for 
receiving the medication).  
 Each variable included in the propensity score should be theoretically 
associated with the primary predictor variable and the outcome variable. It has 
been recommended that models retain non-statistically significant predictors. 
Also, removing pretreatment variables that are weakly associated with the 
outcome will have biasing effects (144, 145). If the propensity score is created 
from only covariates that are statistically significantly different between the 
primary predictor and comparison groups, the score then fails to take into 
account the relationship between the non-predictor variables and the outcome. 
Relying heavily on sample size and not practical relevance causes covariates to 
be considered in isolation rather than collectively (146, 147). Also, if iterative 
model-building algorithms such as stepwise regression are used to select the 
variables included in the propensity score, important confounders that may are 
strongly related to the outcome but only weakly seen in the stepwise regression, 
may not be included (147). Simulation studies have suggested that when 
analyzing moderate-sized data sets, researchers should not exclude any variable 
from the propensity score model unless it is well established that the variable has 
no relationship to the outcome (142). Other studies have suggested that only 
variables that are potential confounders and true confounders should be added 
into the propensity score (148). It has also been suggested that variables 
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included in the propensity score should affect the outcome but not the primary 
predictor variable, and that including variables that affect the primary predictor 
and not the outcome can increase the variance of the estimated treatment effect 
without a reduction in bias (142, 147). 
 Given the lack of consensus on which variables to include in the model, 
and knowing that it is difficult to correctly classify variables into the true 
confounders (i.e. those that only affect the outcome, those that only affect 
primary predictor, and those that affect neither treatment nor the outcome) it is 
advisable to include all measured baseline characteristics in the creation of a 
propensity score (147). 
 Once variable selection is made, the propensity score is then calculated 
as the logit probability (which tends to be normally distributed) or the predicted 
probability. The score is in the form of a continuous value, from 0 to 1, for each 
individual in the study (139, 149).  
 Once the propensity score has been calculated for each of the patients in 
the study, there are a variety of methods used to balance confounding. 
Regression adjustment, stratified regression, or matching models are all common 
approaches (137, 139, 150). Regression adjustment with a propensity score 
occurs when the propensity score is used as an indication variable (indicating the 
propensity to receive a treatment) that is placed into a regression model including 
the primary predictor variable (treatment) and outcome. Propensity score 
stratification occurs when there is stratification of subjects’ based on the 
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individual subjects calculated propensity score. Within each propensity score 
stratum the effect of a treatment on an outcome can be estimated and a more 
specific risk can be estimated based on an individual’s propensity to receive a 
treatment. Matching on a propensity score creates sets of exposed and 
unexposed subjects who share a similar score (a similar indication to receive a 
medication). Once a matched sample has been formed, the treatment effect can 
be estimated by directly comparing outcomes between treated and untreated 
subjects in the matched sample. 
 The propensity score matching approach should fit the research question 
and specific hypotheses of the study. There are many forms of matching such as 
Mahalanobis metric matching, nearest neighbor matching, caliper matching, and 
nearest neighbor matching within a caliper. Nearest neighbor matching within a 
caliper is a combination of matching approaches, and it allows for multivariable 
analysis using the matched sample when the sample is sufficiently large (149, 
151). Nearest neighbor matching with a caliper first randomly sorts both the 
treatment and control groups. Then the first treatment unit is selected to find its 
closest control match based on the absolute value of the difference between the 
propensity score and that of the control under consideration. The closest control 
unit within a certain number, the caliper, is selected as a match (149). Not using a 
caliper can lead to poor balance between the treated and the control (i.e. those 
without the treatment of interest) (151). 
 It is usually always appropriate to adjust for more confounding variables in 
the final model. However, there may be confounding variables that are not 
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included in the propensity score due to temporality concerns (149). Using the 
previous example of antidepressant use in pregnancy and its effects on 
pregnancy, confounding variables (e.g. diagnosis of depression, maternal age) 
would be placed into the propensity score. The calculated propensity score would 
then be used as the matching variable. This balances two non-equivalent groups 
on observed characteristics thus there will be less biased estimates of the effects 
of antidepressant use in pregnancy (152). 
 Propensity scores do not fully control for CBI as they do not account for 
unmeasured confounding. Propensity scores only account for the confounding 
variables included in the creation of the score. Since unmeasured variables can 
influence receipt of the particular predictor variable, propensity scores cannot 
completely remove the bias (149, 153).  
1.3.4 Instrumental Variable Analysis 
 Although typically used in economics, instrumental variable analysis can 
be useful in the determination of CBI. Instrumental variable (IV) analyses makes 
use of an IV or an instrument to control for unmeasured variation between 
confounders. This is different from propensity score matching, which is used to 
controlled for measured variation between confounders (129, 154).  
 An instrument is a seemingly random variable that is strongly associated 
with the predictor variable under study but not associated with the outcome 
(Figure 3) (155). 
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 Finding an ideal instrument for any particular study is complicated. There 
are three key assumptions used in the evaluation of an instrument (155). One,  
the instrumental variable should lead to meaningful differences in the treatment 
being tested. Two, other than through the specific treatment being tested, there 
should be no other pathway for the instrumental variable to influence the 
outcome. Three, the instrumental variable should not cause the patient to receive 
both the instrument and the outcome. Otherwise stated, the IV should be 
independent of any possible confounders, should have association with the risk 
factor, and have independence of the outcome conditional on the risk factor and 
confounders (156). 
 IV’s can vary in strength. The IV is considered weak when the variable 
chosen is not a good estimator of the primary predictor variable and does not 
explain a large proportion of the variation in the primary predictor (157-160). The 
strength of the IV is typically determined by the F-statistic (161). The closer the F-
statistic is to zero, the weaker the instrument. For the maximum bias in IV 
estimators to be less than 10%, the F-statistic should be greater than 10 (157). 
Figure 3. Diagram of Instrumental Variable
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Weak instruments can create biased estimates and confidence intervals that are 
inaccurate (158). Geographic variables from census data are often used as some 
sort of an instrument, though the appropriateness of this instrument is based on 
the dataset being analyzed (162). 
 Use of instrumental variables is normally done via a specific 2-stage 
model. This method is recommended as it is based on the fewest assumptions 
and will generate the most consistent IV estimates, even when the treatment and 
outcome are binary variables (163-165).  However, it can be biased in the 
direction of the confounded association between the primary predictor variable 
and outcome (166). 
 The first stage models the probability of the primary predictor variable as a 
function of all of the confounding variables and the instrumental variable. In 
comparison, the second stage again includes the confounding variables along 
with the predicted probability of the treatment from the first stage (132). The 
output of the model explains the impact of the probability of treatment on the 
outcome versus the presence or absence of the treatment (132, 155). 
 With the previous example of antidepressant use in pregnancy and its 
effects on pregnancy, an instrumental variable could be health insurance status. 
Having health insurance could influence a mother’s ability to obtain 
antidepressants during pregnancy, but should have no influence on the 
development of autism in a child. Health insurance status is then used to remove 
variation in the treatment so that it is free of the unmeasured confounders. Then 
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the confounder-free variation in the treatment  can be used to estimate the 
causal effect of antidepressant use in pregnancy on autism development (159, 
162, 167). 
 The inherent limitation for instrumental variable analyses is their strong 
dependence on the assumption that the instrument is independent of all the 
variables that have an effect on both the predictor variable and the outcome 
variable, and that the instrument is independent of the outcome variable (132). 
Instrumental variable analysis is a large-sample procedure, meaning there is 
some bias due to sample-size limitations, even if all the assumptions of an 
appropriate instrument are met (132, 168). 
1.5 Conclusions 
 Current guidelines for the treatment of hospitalized patients with CAP 
include empiric antimicrobial therapy with a macrolide plus a beta-lactam. There 
is little consensus among studies as to which antimicrobial regimen is best.  The 
confusing results seen may be due to a lack of assessment of CBI. Thus, the 
objective of this study is to evaluate the impact of empiric macrolide therapy on 
early clinical improvement and 30 day mortality of hospitalized patients with CAP.  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AIMS AND HYPOTHESES 
2.1.1  Aim: 
 To evaluate three years of study data and determine whether macrolide 
and beta-lactam combination therapy usage is appropriate for gold standard 
treatment in hospitalized community acquired pneumonia though assessment of 
ECS and 30 day mortality. 
2.1.2  Hypothesis: 
 Patients with macrolide and beta-lactam combination therapy will reach 
ECS and will have decreased 30 day mortality compared to those who have 
been given a different antibiotic.  
2.2.1  Aim: 
 To assess and compare various methods addressing CBI (multivariable 
logistic regression, propensity score stratification and matching, instrumental 
variable analysis) through the assessment of macrolide and beta-lactam 
combination therapy and its effect on ECS and 30 day mortality in hospitalized 
patients with community acquired pneumonia. 
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2.2.2 Hypothesis: 
 The three methods assessing CBI will show the same effects of macrolide 
and beta-lactam combination therapy on ECS and 30 day mortality. 
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MATERIALS AND METHODS 
3.1 Study 
 This is a secondary analysis of years one, two, and three of the 
Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study (HAPPI). 
This study was conducted in Jefferson County, Kentucky from 2014 to 2017. It 
was a prospective population based cohort of adults hospitalized with CAP within 
the participating hospitals (n=8839) (7). 
 The study was approved by the Institutional Review Board (IRB) at the 
University of Louisville Human Subjects Research Protection Program Office 
(IRB number 11.0613) and by the research offices at each participating hospital. 
The study was exempt from informed consent.  
3.1 Inclusion Criteria 
 Patients with CAP in one of nine area hospitals in Jefferson County, 
Kentucky were recruited into the study. The nine area hospitals included Baptist 
East Hospital, Jewish Hospital, Norton Audubon Hospital, Norton Brownsboro 
Hospital, Norton Downtown Hospital, Norton Suburban Hospital, St. Mary and 
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Elizabeth Hospital, University Hospital, and Veteran’s Affairs Hospital.  A patient 
was defined as having CAP when the following 3 criteria were met: (1) presence 
of a new pulmonary infiltrate on chest radiograph and/or chest computed 
tomography scan at the time of hospitalization, defined by a board-certified 
radiologist’s reading; (2) at least 1 of the following: (a) new cough or increased 
cough or sputum production, (b) fever >37.8°C (100.0°F) or hypothermia <35.6°C 
(96.0°F), (c) changes in leukocyte count (leukocytosis: >11000 cells/µL; left shift: 
>10% band forms/mL; or leukopenia: <4000 cells/µL); and (3) no alternative 
diagnosis at the time of hospital discharge that justified the presence of criteria 1 
and 2 (7). These criteria were adapted from prior investigations (169, 170). 
Patients with CAP were included in this analysis upon the determination of 
antibiotic use within the first 24 hours of admission.  
3.2 Exclusion Criteria 
 Patients were excluded from HAPPI if they did not have a permanent or 
valid Jefferson County, KY address based on US Census Bureau data, did not 
have a valid Social Security number (SSN), or were in the correctional system 
(7). Patients missing data needed to determine ECS were excluded in this 
analysis. Patients were also excluded from this analysis if they were given both a 
macrolide and a fluoroquinolone, or a non-macrolide and non-beta-lactam 
combination therapy with a non-fluoroquinolone substitute in the first 24 hours.  
!38
After exclusion and missing data attrition, the study sample size for this analysis 
was 3142 participants (Figure 4). 
3.3 Exposure: Macrolide Usage 
  
 Two groups were created from the patients that were included in this 
analysis.  Group 1 consisted of patients who received a macrolide plus a beta-
lactam in the first 24 hours of admission but did not receive a fluoroquinolone, 
n=1904 (Figure 4). Macrolide antimicrobials are as follows: Azithromycin, 
Clarithromycin, and Erythromycin. Beta-lactam antimicrobials are as follows: 
Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cefaclor, 
Cefazolin, Cefepime, Cefixime, Cefoperazone, Cefoperazone-Sulbactam , 
Cefotaxime, Cefotetan, Cefpodoxime, Ceftazidime, Ceftriaxone, Cefuroxime, 
Cephalexin, Cloxacillin, Dicloxacillin, Imipenem/Cilastin, Meropenem, Nafcillin, 
Penicillin, Penicillin G, Piperacillin, Piperacillin/Tazobactam, and Ticarcillin/
Clavulanic acid.  
 Group 2 consisted of patients who received a non-macrolide regimen, 
n=1238 (Figure 4). Quinolone antimicrobials are as follows: Levofloxacin, 
Gatifloxacin, Moxifloxacin and Ciprofloxacin. 
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3.4.1 Outcome: Early Clinical Stability 
 Clinical stability is defined according to the ATS guidelines published in 
2001. The ATS criteria are as follows: improved symptoms of pneumonia (cough 
and shortness of breath), lack of fever for at least eight hours, improving 
leukocytosis (decreased at least 10% from the previous day), and ability to take 
oral medications (97). All the criteria should be present during the same day in 
8839 Living in Jefferson County
8772 Antibiotic information
8769 Admission data
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  Figure 4. Flow chart showing sample selection for analysis
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comparison to the previous day to define clinical stability (97). For this study, 
ECS was to have occurred when the criteria were met on or before the third day 
of hospitalization. The dependent variable of this study was ECS by day 3 of 
hospitalization.  
3.4.3 Outcome: 30 Day Mortality 
 The outcome of 30 day mortality was defined as all-cause mortality up to 
30 days after hospitalization. Mortality was obtained through medical record 
abstraction and using data from the Kentucky Department for Public Health 
Office of Vital Statistics (7). 
3.5.1 Other Variables 
 The original HAPPI study collected more than 600 variables. As analyzing 
all of these variables is outside the scope of this analysis, a determination of 
what variables to include was necessary. The variables included in the statistical 
analysis were important to the risk of CAP, associated with macrolide usage, 
associated with ECS, factors in clinical presentation, or were demographic 
variables. Demographic variables included were age, sex and race. Medical 
history variables included history of intravenous (IV) drug use, alcoholism, 
asplenia, chronic renal failure, congestive heart failure (CHF), cirrhosis, chronic 
obstructive pulmonary disease (COPD),  cerebrovascular disease (CVD), human 
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immunodeficiency virus (HIV), diabetes, history of IV steroid use before day 0 of 
admission, liver disease, history of neoplastic disease within the last year or 
current neoplastic disease, renal disease, residence in a nursing home, current 
smoker status, and suspicion of risk for aspiration. Variables that were collected 
in the initial physical exam in the hospital included body mass index (BMI), 
diastolic blood pressure (DBP), systolic blood pressure (SBP), heart rate (HR), 
respiratory rate (RR), temperature, and weight. Variables that were found on the 
initial physical exam in the hospital included body mass index (BMI), diastolic 
blood pressure (DBP), systolic blood pressure (SBP), heart rate (HR). respiratory 
rate (RR), temperature, and weight. Initial laboratory finding variables included 
blood urea nitrogen (BUM), serum glucose, hematocrit percent, and serum 
sodium. Variables that influenced the level of severity of CAP include altered 
status on admission, being admitted directly to the intensive care unit from the 
emergency department, requiring vasopressors on day 0 of admission, and 
requiring ventilatory support on day 0 of admission. Another variable considered 
was the classification of “severe”. This variable was created from a score based 
on the severity criteria recommended by the ATS/IDSA and compiled from the 
following variables (3, 171):  
- Respiratory rate >30 breaths per minute 
- Partial pressure of oxygen dissolved in the blood divided by fractional 
inspired oxygen (PaO2/FiO2) </=250 
- Multi-lobar pneumonia as seen on a CT 
- BUN >/= 20 mg/dL 
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- Leukopenia (white blood count >20,000/microL) 
- Thrombocytopenia (platelets <100,000/microL) 
- Hypothermia (temperature < 36 degrees Celsius) 
- Hypotension (SBP<90mmHg and DBP<60mmHg 
- Ventilator type (nasal intermittent mandatory ventilation (NMIV)) 
- Altered mental status on admission 
- Septic shock 
- Vasopressor medication 
Census tract block information from patients was used in the instrumental 
variable analysis.  
3.5.2 Instrumental Variable 
 Area Deprivation Index (ADI) was assessed as an appropriate 
instrumental variable. ADI is defined as a geographic area-based measure of the 
socioeconomic deprivation experienced by a neighborhood and is determined 
from census information. Higher ADI values represent higher levels of deprivation 
(172). ADI is based on the following indicators: median family income, income 
disparity, occupational composition, unemployment rate, family poverty rate, 
percentage of the population below 150% of the poverty limit, single-parent 
household rate, home ownership rate, median home value, median gross rent, 
median monthly mortgage, household crowding, and percentages of households 
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without access to a telephone, plumbing, or motor vehicles. Factor analysis and 
principal-components analysis were used in index construction (173). 
3.6.1 Sample Size and Statistical Power 
 The initial study sample had 8839 participants, but after attrition due to 
exclusion criteria and missing data, the total sample size was 3,142, with 1,904 in 
group 1 and 1,238 in group 2.  
 Of those who gained ECS (n=2,018), 57.7% were given macrolide and 
beta-lactam combination therapy (n=1,205). The risk of ECS among group 1 was 
63.29%. The risk of ECS among group 2 was 65.67%. Given the expected 
frequencies of exposure, an OR of 1.28 at 80% power and 1-alpha of 95% is 
detectable, the inverse of which is an OR of 0.78. Although, with the given 
sample size, a post hoc power analysis showed the statistical analysis of ECS 
was under-powered at 27.81% (174).  
 Of those who died within 30 days of discharge from the hospital  (n=224), 
60.3% were given macrolide and beta-lactam combination therapy (n=125). The 
risk of 30 day mortality among group 1 was 7.09%. The risk of ECS among group 
2 was 7.19%. Given the frequencies of exposure, an OR of 1.5 at 80% power 
and 1-alpha of 95% is detectable, the inverse of which is an OR of 0.67. 
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However, with the given sample size, a post hoc power analysis showed the 
statistical analysis for 30 day mortality was under-powered at 2.18% (174). 
 Further statistical analysis were performed using STATA 14 and R.  
 Fisher's Exact Test was used on categorical variables and the Mann-
Whitney U/ Wilcoxon Sum-rank test was used on continuous variables to 
understand the characteristics of the population and to assess variables for 
inclusion in further analysis. Inclusion was determined to occur at a conservative 
p-value of <0.20. Variables initially included were organized by type - 
demographic variables, medical history, physical findings on initial exam, 
laboratory findings on initial exam, and severity of CAP (Table 4). 
3.6.2 Statistical Analysis of Confounding and Confounding By Indication 
 The effect of macrolide usage on ECS was assessed using multiple 
statistical methods: multivariable logistic regression, stratification using the 
propensity score, propensity score matching, and instrumental variable analysis. 
After the primary analysis determining which variables are statistically 
significantly different between the two groups, using P<= 0.2, the significant 
variables were placed into the multivariable logistic regression model.  The final 
model was determined through a data-based method for assessment (125). A full 
model with the statistically significant variables was made. Then starting with the 
full model each covariate was removed, one at time. When the beta coefficient of 
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macrolide and beta-lactam therapy was more than 10% different than original full 
model beta coefficient of macrolide and beta-lactam therapy, the variable will be 
considered for the full model. The variable that was least significant, the one with 
the largest P value that did not affect the beta coefficient of macrolide and beta-
lactam therapy more than 10%, was removed and the remaining variables went 
through the same process till only the confounding variables remained. A 
bidirectional stepwise method was also used, which is a mix of the forward and 
backward methods. (Forward stepwise regression is when variables are 
introduced one by one, beginning with the strongest, and then stopping when 
addition of the next factor does not significantly improve AIC. Backward stepwise 
regression is where all the variables are initially introduced and then are 
withdrawn one by one until the overall AIC does not deteriorate (175, 176).) The 
results of the bidirectional stepwise method were compared to the data-based 
method for assessment.

	 Propensity scores were calculated by a logit regression. The propensity 
score was created using all of the demographic characteristic variables, except 
for those that were included in the severity score (Table 4) (142, 143). These 
variables were:  age, sex, race, mental status, history of neoplastic disease, CHF, 
CVA, COPD, renal disease, chronic renal failure, liver disease, cirrhosis, 
asplenia, alcoholism, suspicion of aspiration, IV steroid use, IV drug use, HIV, 
nursing home status, smoking status, direct ICU admission, exam HR, exam 
BMI, hematocrit laboratory values, glucose laboratory values, and sodium 
laboratory values. The propensity score was established by creating the 
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predicted probability of receiving the macrolide and beta-lactam combination 
treatment given the set of variables described above. 
 Propensity scores were used to stratify the population. Patients were 
ranked according to propensity score and stratified into propensity score 
quintiles, an approach that is known to remove the majority of bias in measured 
covariates (177). Also, patients receiving macrolide and beta-lactam combination 
therapy (group 1) were matched with patients that did not receive the 
combination therapy (group 2) according to their propensity scores. The 1:1 
matched analysis was performed using caliper width based on the propensity 
score (178). The caliper width was determined by taking the standard deviation 
of the propensity score and multiplying it by 0.25. 
 Instrumental Variable Analysis were performed using the multivariable 
logistical regression and the two stage probit model with a significant instrument, 
that was determined by the F-statistic being greater than 10. The probit 
coefficient created by the model was multiplied by 1.6 and then exponentiated to 
approximate an Odds Ratio (OR) such that the outcomes of the various methods 
for addressing confounding by indication could be compared to one another 
(165).  
 The results from the different models were compared by placing them into 
a forest-like plot. A confidence interval that excluded the OR’s from other 




	 In the original study population, there were 8,839 participants with CAP 
included who all lived in Jefferson County. 8,772 had antibiotic information listed, 
with 8,769 of those having admission data. There were only 8,479 participants 
who received an antibiotic within the first 24 hours. Of these, only 3,141 received 
either macrolide and beta-lactam combination therapy (N=1,905)  or 
flouroquinolone mono-therapy (N=1,238) (Figure 4).  
 Table 4 shows descriptive statistics for the study population. Among the 
demographic variables neither sex nor race were significantly different between 
the groups. Age was significantly different between the groups, p=0.001, with 65 
as the mean age in group 1 and 67 as the mean age in group 2 (Table 4).

 Of the medical history variables, history of intravenous drug use, CHF, 
cirrhosis, COPD, history of IV steroid use before day 0 of admission, residence in 
a nursing home, and current smoker status were significantly different between 
the two different groups, given p<0.2 (Table 4). Interestingly, nursing home status 
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was most significant (p=<0.001) with 74 in a nursing home in group 1 (4%) and 
102 in a nursing home in group 2 (8%). 
 Of the variables that were found on the initial physical exam in the hospital 
DBP, SBP, HR and RR were all significantly different between groups (given 
p<0.2), with p-values of  <0.001, 0.001, 0.002, and <0.001, respectively (Table 4).  
 From the initial laboratory finding variables, hematocrit percent was found to 
be significantly different (given p<0.2) between the two groups, (p=0.001) (Table 
4). The mean hematocrit percentage was 36.1% in group 1 and 36.9% in group 
2. Serum glucose was also noted to be different between the two groups, 
p=0.012, with 170 mg/dL the mean in group 1 and 160 mg/dL the mean in group 
2. 
 Of the variables that influenced the severity of CAP, ventilator support on 
day zero was significant (given p<0.2), p=0.032, with 179 (9%) in group 1 and 84 
(7%) in group 2 (Table 4).  
 Severe was a significant variable (given p<0.2), p=0.005, with 602 people in 
group 1 and 333 in group 2. There were many variables that were included in the 
severe variable that were also examined. Some of these variables were 
independently significant while others were not. To prevent variables from being 
used twice in the analysis, the decision was made to include the severe variable 
as it carries a wider range of disease information with it.  
 Other correlated variables were COPD and IV steroid use before day 0 of 
admission (0.3414, p-value=< 0.001). This correlation is most likely a result of IV 
steroids given for exacerbations COPD (179).  
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African American/Black, n (%) 376 (20) 239 (19) 0.783
Age, Mean (SD) 65 (17) 67 (16) 0.001+
Male Gender, n (%) 840 (44) 540 (44) 0.797
Medical History
Active intravenous drug use?, n (%) 31 (2) 10 (1) 0.053+
Alcoholic, n (%) 96 (5) 58 (5) 0.673
Asplenia, n (%) 4 (0) 3 (0) >0.999
Chronic renal failure, n (%) 120 (6) 80 (6) 0.881
Congestive heart failure, n (%) 481 (25) 343 (28) 0.135+
Cirrhosis, n (%) 16 (1) 4 (0) 0.106+
COPD, n (%) 868 (46) 617 (50) 0.019+
Cerebrovascular disease, n (%) 206 (11) 138 (11) 0.770
Diabetes, n (%) 589 (31) 368 (30) 0.500
HIV, n (%) 25 (1) 16 (1) >0.999
IV steroids on day 0, n (%) 598 (31) 343 (28) 0.028+
Liver disease, n (%) 127 (7) 71 (6) 0.329
Neoplastic disease (active or within the last 
year), n (%)
204 (11) 141 (11) 0.56
Renal disease, n (%) 469 (25) 309 (25) 0.833
Nursing home resident, n (%) 74 (4) 102 (8) <0.001+
Current smoker, n (%) 689 (36) 396 (32) 0.017+
Suspicion of aspiration, n (%) 132 (7) 87 (7) 0.943
+, variables will be included in further analysis as p-value<0.2  
**, variables will not be included in analysis due to the inclusion in severity variable
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Physical Findings on Initial Exam
BMI (kilograms/meter^2), Mean (SD) 29.1 (9) 28.8 (8.6) 0.476
Diastolic blood pressure (mmHg), Mean (SD) 60.8 (17.9) 63.5 (17) <0.001**
Systolic blood pressure (mmHg), Mean (SD) 121.2 (27.4) 124.1 (25.9) 0.001**
Heart rate (Beats/Minute), Mean (SD) 105.2 (22.1) 102.8 (21.5) 0.002+
Respiratory rate (Breaths/Minute), Mean (SD) 23.7 (6.5) 23 (6.5) <0.001**
Temperature (Degrees Celsius), Mean (SD) 37.4 (9) 37.4 (0.8) 0.798**
Weight (kilograms), Mean (SD) 82.6 (27) 82 (26) 0.555
Initial Laboratory Findings
Blood Urea Nitrogen (BUN) (mg/dL), Mean 
(SD)
22.1 (16.4) 21.2 (13.8) 0.696**
Serum glucose (mg/dl), Mean (SD) 170.4 (88.6) 160.8 (78) 0.012+
Hematocrit(%), Mean (SD) 36.1 (6.1) 36.9 (6) 0.001+
Serum sodium (mEq/L), Mean (SD) 136.7 (5) 136.5 (4.6) 0.297
Severity of CAP
CAP diagnosis is considered severe, n (%) 602 (32) 333 (27) 0.005+
Altered mental status on admission, n (%) 219 (11) 139 (11) 0.863**
Was the patient admitted directly to an 
intensive care unit from the emergency 
department?, n (%)
188 (10) 108 (9) 0.289
Did the patient need vasopressors on day 0?, 
n (%)
24 (1) 14 (1) 0.868**
Did the patient need ventilatory support on day 
0?, n (%)
170 (9) 84 (7) 0.032**
+, variables will be included in further analysis as p-value<0.2  
**, variables will not be included in analysis due to the inclusion in severity variable
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 Variables included in further analysis were as follows: age, cirrhosis, 
COPD, CHF, history of IV drug use, being in a nursing home, currently smoking, 
HR, hematocrit, glucose, and severity.  
4.2.1 Assessment of Macrolide Combination Therapy and the Effects on Early 
Clinical Stability: Logistic Regression 
 Patients on macrolide and beta-lactam combination therapy were less 
likely to reach ECS than those taking fluoroquinolones,  although this is a non 
significant result (OR 0.901; 95% Confidence Interval (CI) 0.776, 1.047; p-value: 
0.173) (Table 5). 
  
 In the full model including all the variables that were found to be 
significantly different (given p<0.2) between group 1 and 2 (age, cirrhosis, COPD, 
CHF, history of IV drug use, being in a nursing home, currently smoking, HR, 
hematocrit, glucose, and severity) macrolide combination therapy was found to 
decrease the likelihood of reaching ECS, although this also was non-significant 
(OR 0.911; 95% CI 0.780, 1.063; p-value = 0.235). Significant variables in this 
model were COPD (OR 0.747; 95% CI 0.638, 0.875; p-value =<0.001), HR (OR: 
0.992; 95% CI 0.988, 0.995; p-value =<0.001), CHF (OR 0.802; 95% CI 0.675, 
0.953 ; p-value =0.012), and severity (OR 0.611; 95% CI 0.519, 0.721; p-value 
=<0.001) (Table 5). 
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 The bidirectional stepwise analysis algorithm yielded the same model 
results that the data-based method of variable selection did (both algorithms 
used macrolide combination therapy as the primary predictor variable). The 
model was as follows: logit P(ECS) = ⍺ + β1(macrolide and beta-lactam 
combination therapy) + β2(COPD) + β3(CHF) + β4(residence in a nursing home) + 
β5(HR) + β6(severity) + ε. The reduced model was not statistically different from 
the full model and was thus considered acceptable (Chi-Square P-value = 
0.8641289). In the final model, macrolide and beta-lactam use was associated 
with decreased odds of gaining ECS, although this was once again not 
statistically significant (OR 0.910; 95% CI 0.780, 1.061; p-value =0.227). The 
variables in this model that were significantly associated with increased time to 
clinical stability were COPD (OR 0.735; 95% CI 0.633, 0.854; p-value =<0.001), 
HR (OR: 0.992; 95% CI 0.988, 0.995; p-value =<0.001), CHF (OR 0.810; 95% CI 
0.675, 0.953 ; p-value =0.015), and severity (OR 0.617; 95% CI 0.526, 0.725; p-
value =<0.001) (Table 5). The full process for variable selection using a data-
based method is presented in Appendix II (ECS: Multivariable Logistic 
Regression, Data-based Method for Assessment).  
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Table 5. Multivariable Logistic Regression Models: ECS
Variable OR 95% CI P-Value
Univariate Model
Macrolide + Beta Lactam Therapy 0.901 0.776, 1.047 0.173
Full Model
Macrolide + Beta Lactam Therapy 0.911 0.780, 1.063 0.235
Age         >0.999  0.995, 1.005 0.984
Glucose    >0.999  0.999, 1.001 0.756
Smoking 0.954 0.802, 1.136 0.599
IV drug use   0.818 0.427, 1.565 0.543
Cirrhosis     0.738 0.302, 1.805 0.506
Hematocrit   0.993 0.981, 1.006 0.301
Residence in nursing home 0.740 0.537, 1.018 0.065
CHF        0.802 0.675, 0.953 0.012 +
COPD          0.747 0.638, 0.875 <0.001 +
HR          0.992 0.988, 0.995 <0.001 +
Severe           0.611 0.519, 0.721 <0.001 +
Final Model
Macrolide + Beta Lactam Therapy 0.910 0.780, 1.061 0.227
Residence in nursing home 0.752 0.548, 1.032 0.078
CHF        0.810 0.683, 0.959 0.015 +
COPD          0.735 0.633, 0.854 <0.001 +
HR          0.992 0.988, 0.995 <0.001 +
Severe           0.617 0.526, 0.725 <0.001 +
+ statistically significant
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4.2.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day 
Mortality: Logistic Regression 
 Assessing the unadjusted effects of macrolide and beta-lactam 
combination therapy and its effect on 30 day mortality showed that those with 
macrolide and beta-lactam combination therapy were less likely to have died 
within 30 days of admission,  although this is a non-significant result (OR 0.985; 
95% Confidence Interval (CI) 0.746, 1.301; p-value:  0.916) (Table 6). 
  
 The full model including all the variables that were found to be significantly 
different (given p<0.2) between group 1 and 2 (age, cirrhosis, COPD, CHF, 
history of IV drug use, being in a nursing home, currently smoking, HR, 
hematocrit, glucose, and severity) macrolide combination therapy was found to 
decrease 30 day mortality, although this again was non significant (OR 0.911; 
95% CI 0.780, 1.063; p-value = 0.235). Significant variables in this model were 
Age (OR 1.04; 95% CI 1.029, 1.052; p-value =<0.001), HR (OR: 1.014; 95% CI 
1.007, 1.020; p-value =<0.001), IV drug use (OR 3.486; 95% CI 1.121, 10.838 ; 
p-value =0.031), hematocrit (OR 0.950; 95% CI 0.928, 0.973 ; p-value =<0.001), 
and severity (OR 2.237; 95% CI 1.675, 2.987; p-value =<0.001) (Table 6). 
 The bidirectional stepwise analysis algorithm produced a different model 
result than the data-based method variable selection (both algorithms used 
macrolide combination therapy as the primary predictor variable).  Both models 
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included residence in a nursing home, history of IV drug use, hematocrit lab 
values, HR, severity, and age. The bidirectional stepwise method included CHF 
while the data-based method included glucose values.  Neither the bidirectional 
stepwise method nor the data-based method were statistically different from the 
full model, Chi-Square P-value of 0.3306626 and 0.4590019, respectively. The 
data-based method model was less different from the full model compared to the 
bidirectional stepwise method. The model was as follows: logit P(30 Day 
Mortality) = ⍺ + β1(macrolide and beta-lactam combination therapy) + 
β2(residence in a nursing home) + β3(glucose) + β4(IV drug use) + β5(hematocrit) 
+ β6(HR) + β7(severe) + β8(age) + ε. 
In the final model, those with macrolide and beta-lactam use were less 
likely to have died within 30 days of admission, although this was not statistically 
significant (OR 0.926; 95% CI 0.692, 1.241; p-value =0.608). The variable in this 
model that was significantly associated with reduced mortality was hematocrit 
(OR: 0.950; 95% CI 0.928, 0.973; p-value =<0.001). The variables in this model 
that were significantly associated with increased 30 day mortality were IV drug 
use (OR 3.548; 95% CI 1.160, 10.854; p-value =0.026), HR (OR 1.013; 95% CI  
1.007, 1.019 ; p-value =<0.001), severity (OR 2.290; 95% CI 1.717, 3.052; p-
value =<0.001), and age (OR 1.042; 95% CI 1.031, 1.053; p-value =<0.001) 
(Table 6). The full process for variable selection using a data-based method is 
presented in Appendix II (30 Day Mortality: Multivariable Logistic Regression, 
Data-based Method for Assessment).  
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Table 6. Multivariable Logistic Regression Models: 30 Day Mortality
Variable OR 95% CI P-Value
Univariate Model
Macrolide + Beta Lactam Therapy 0.985 0.746, 1.301 0.916
Full Model
Macrolide + Beta Lactam Therapy 0.929 0.780, 1.063 0.235
Smoking 0.955  0.663, 1.376 0.804
COPD          1.068 0.795, 1.435 0.663
CHF         1.221 0.902, 1.653 0.196
Residence in nursing home 1.387 0.856, 2.248 0.184
Cirrhosis     2.486 0.690, 8.963 0.164
Glucose      1.001 1.000, 1.003 0.094
IV drug use     3.486 1.121, 10.838 0.031 +
Hematocrit   0.950 0.928, 0.973 <0.001 +
HR          1.014 1.007, 1.020 <0.001 +
Severe           2.237 1.675, 2.987 <0.001 +
Age          1.040 1.029, 1.052 <0.001 +
Final Model
Macrolide + Beta Lactam Therapy 0.926  0.692, 1.241 0.608
Glucose      1.001 1.000, 1.003 0.066
Residence in nursing home 1.390 0.859, 2.249 0.180
IV drug use     3.548 1.160, 10.854 0.026 +
Hematocrit   0.950 0.928, 0.973 <0.001 +
HR          1.013  1.007, 1.019 <0.001 +
Severe           2.290 1.717, 3.052 <0.001 +
Age          1.042 1.031, 1.053 <0.001 +
+ statistically significant
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4.3.1 Propensity Score Creation 
 The calculated propensity score ranged from 0.2718 to 0.9007 as depicted 
in the histogram in Figure 5. The mean propensity score was 0.6060 with a 
standard deviation of 0.0869. Group 1 had a mean of 0.6184 while group 2 had a 
mean of 0.5868 and were statistically different from one another (p= <0.001) 
(Figure 6). The propensity scores between the two groups, while visually similar, 
are not statistically similar, meaning that on average, those who were given 
fluoroquinolone mono-therapy had a slightly lower probability of being given 
macrolide and beta-lactam combination therapy. 
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Histogram of Propensity Score
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 Using the calculated propensity score, patients in group 1 were matched 
with patients in group 2. Nearest neighbor matching with a caliper was used to 
create the matches. The caliper, 0.02173275, was based on the standard 
deviation of the propensity score, multiplied by 0.25. Of the original 3142 
patients, 1177 matched pairs were created, leaving 61 people in group 2 
unmatched and 727 people in group 1 unmatched (Figure 7, Figure 8). 
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Figure 7: Distribution of Propensity Scores
Figure 8: Distribution of Propensity Scores, Matched vs Unmatched
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4.3.2 Assessment of Macrolide Combination Therapy and the Effects on Early 
Clinical Stability: Propensity Score Analysis 
  
 Using conditional logistic regression, macrolide and beta lactam usage 
was found to decrease the likelihood of gaining clinical stability, although this was 
non-significant (OR 0.885, 95% CI 0.748, 1.048, p-value = 0.156) (Table 7). 
 When the propensity scores were stratified based on quartile values, the 
effect of macrolide and beta-lactam combination therapy on ECS was assessed 
using logistic regression. While none of the values were significant, the effect of 
macrolide and beta-lactam combination therapy on establishing ECS did change 
depending on the propensity score value (Table 7). 
Table 7. Effects of Macrolide and Beta-Lactam Combination Therapy on ECS, by Propensity 
Score
Model OR 95% CI P-value
Conditional Logistic Regression
Matched 1:1 0.885 0.748, 1.048 0.156
Stratification by PS
Q1 0.0001 - 0.5571 0.888 0.660, 1.196 0.435
Q2 0.5572 - 0.6109 0.927 0.684, 1.257 0.625
Q3 0.6110 - 0.6631 1.023 0.755, 1.386 0.884
Q4 0.6632 - 1.0000 0.929 0.679, 1.271 0.646
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4.3.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day 
Mortality: Propensity Score Analysis 
 Using conditional logistic regression, macrolide and beta lactam usage 
was found to decrease 30 day mortality, although this was non-significant (OR 
0.848, 95% CI 0.612, 1.174, p-value = 0.321) (Table 8). 
 When the propensity scores were stratified based on quartile values, the 
effect of macrolide and beta-lactam combination therapy on 30 day mortality was 
assessed using logistic regression. While none of the values were significant, the 
effect of macrolide and beta-lactam combination therapy on 30 day mortality did 
change depending on the propensity score value, particularly in the third quartile 
(Table 8). 
Table 8. Effects of Macrolide and Beta-Lactam Combination Therapy on 30 Day Mortality by 
Propensity Score
Model OR 95% CI P-value
Conditional Logistic Regression
Matched 1:1 0.885 0.748, 1.048 0.156
Stratification by PS
Q1 0.0001 - 0.5571 0.955 0.566, 1.612 0.863
Q2 0.5572 - 0.6109 0.954 0.501, 1.815 0.885
Q3 0.6110 - 0.6631 1.240 0.697, 2.207 0.465
Q4 0.6632 - 1.0000 0.797 0.465, 1.366 0.409
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4.4.1 Assessment of Macrolide Combination Therapy and the Effects on Early 
Clinical Stability: Instrumental Variable Analysis 
 Instrumental variable analysis was done via a two stage model where the 
first-stage was a regression of macrolide and beta-lactam combination therapy 
and other variables on the instrumental variable, ADI. The second-stage was a 
regression of ECS on the fitted values of the risk factors from the first stage. ADI 
was considered a strong instrument as the F-statistic was greater than 10 (F-
statistic 12.62; p-value <0.001). The model used in this analysis included the 
variables selected in logistic regression modeling, COPD + CHF + residence in a 
nursing home + HR + severity.  
 While the confidence interval was very wide and non-significant, it is 
interesting to note that macrolide and beta-lactam combination therapy was 
associated with reaching ECS (OR 1.551; 95% CI 0.778, 3.091; p-value = 0.213). 
The significant variables in this model were CHF (OR 0.935; 95% CI 0.876, 
0.999; p-value = 0.046), COPD (OR 0.915; 95% CI 0.858, 0.976; p-value = 
0.007), HR (OR 0.996; 95% CI 0.995, 0.998; p-value = <0.001), and Severity 
(OR 0.810; 95% CI 0.750, 0.874; p-value = <0.001) (Table 9).  
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4.4.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day 
Mortality: Instrumental Variable Analysis 
 Instrumental variable analysis was done via the two stage model. ADI was 
again considered a strong instrument as the F-statistic was greater than 10 (F-
statistic 11.03; p-value <0.001). The model used in this analysis included the 
variables selected in logistic regression modeling, glucose + residence in a 
nursing home + history of IV drug use + hematocrit lab values + HR + severity + 
age. 
 While the confidence interval was non-significant, macrolide and beta-
lactam combination therapy was associated with a slight decrease in the 
likelihood of dying within 30 days (OR 0.958; 95% CI 0.603, 1.522; p-value 
=0.857). The significant variables in this model were hematocrit (OR 0.995; 95% 
Table 9. Instrumental Variable Analysis with ADI as the Instrument: ECS
Variable OR 95% CI P-Value
Macrolide + Beta Lactam Therapy 1.551 0.778, 3.091 0.213
Residence in nursing home 0.989 0.824, 1.187 0.907
CHF        0.935 0.876, 0.999 0.046 +
COPD          0.915 0.858, 0.976 0.007 +
HR          0.996 0.995, 0.998 <0.001 +
severe           0.810 0.750, 0.874 <0.001 +
+ statistically significant
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CI 0.991, 0.998; p-value = 0.002), HR (OR 1.002; 95% CI 1.001, 1.002; p-value = 
<0.001), severity (OR 1.108; 95% CI 1.064, 1.154; p-value = <0.001), and age 
(OR 1.003; 95% CI 1.002, 1.005; p-value = <0.001) (Table 10).  
4.2.5 Assessment of Methods Addressing Confounding by Indication: Logistic 
Regression, Propensity Score Matching, Instrumental Variable Analysis 
 Figures 8 and 9 compare the results from the three methods for controlling 
confounding and confounding by indication in a forest plot. Examining the 
methods used to assess the effects of macrolide and beta-lactam combination 
therapy on ECS, the OR’s of all three methods have non-significant intervals and 
the OR’s from logistic regression and propensity score matching are almost 
Table 10. Instrumental Variable Analysis with ADI as the Instrument: 30 Day Mortality
Variable OR 95% CI P-Value
Macrolide + Beta Lactam Therapy 0.958 0.603, 1.523 0.857
Glucose 1.000 1.000, 1.000 0.217
Residence in nursing home 1.052 0.944, 1.173 0.359
IV drug use 1.105 0.966, 1.264 0.145
Hematocrit 0.995 0.991, 0.998 0.002 +
HR 1.002 1.001, 1.002 <0.001 +
Severe 1.108 1.064, 1.154 <0.001 +
Age 1.003 1.002, 1.005 <0.001 +
+ statistically significant
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identical, 0.918 and 0.916 respectively, (Table 9). The methods used to assess 
the effects of macrolide and beta-lactam combination therapy on 30 day mortality 
all had similar OR’s with non significant intervals (Figure 9, Table 9). The 
confidence intervals from the instrumental variable analyses preformed are larger 
than those from logistic regression and propensity score matching.  
  
Table 11. Comparing Logistic Regression, Propensity Score Matching, and Instrumental 
Variable Analysis
Method OR 95% CI
ECS
Logistic Regression 0.908 0.780, 1.059
Propensity Score Match 0.916 0.775, 1.083
Instrumental Variable Analysis 1.551 0.777, 3.091
30 Day Mortality
Logistic Regression 0.926  0.692, 1.241
Propensity Score Match 0.885 0.748, 1.048




Figure 8: Forest-like Plot, Effect of Macrolide and Beta-Lactam Combination Therapy 
on ECS
Figure 9: Forest-like Plot, Effect of Macrolide and Beta-Lactam Combination Therapy 
on 30 Day Mortality
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DISCUSSION 
5.1 Discussion of Macrolide and Beta-Lactam Combination Therapy and Early 
Clinical Stability 
 The first objective of this analysis was to determine whether macrolide and 
beta-lactam combination therapy usage is appropriate for gold standard 
treatment in hospitalized CAP though the assessment of ECS. Overall, macrolide 
and beta-lactam combination therapy was not associated with ECS compared to 
fluoroquinolone mono-therapy. 
 When evaluating the effects of macrolide and beta-lactam usage on ECS, 
there was a difference in the results depending on the method used to address 
CBI. Analysis with logistic regression and propensity score matching, both 
addressing measured confounding, showed that macrolide and beta-lactam 
therapy was not statistically significantly associated with ECS based on 
confidence intervals and p-values, but both odds ratios were less than 1.0 
suggesting protection against establishing ECS. This suggests that, according to 
these methods for controlling for CBI, macrolide and beta-lactam combination 
therapy was associated with decreased likelihood of reaching clinical stability by 
day three. Analysis using ADI in instrumental variable analysis addressed 
unmeasured confounding and also showed statistically non-significant results. 
However the calculated odds ratio suggested that macrolide and beta-lactam 
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combination therapy usage was associated with increasing likelihood of 
establishing clinical stability on or before day three.  
 The variation in the odds ratios calculated via the three different methods 
suggests there may be unmeasured variables that are important in establishing 
ECS that are not being addressed in logistic regression and propensity score 
matching. Variables indicated by ADI (a proxy variable) but not actively measured 
could be playing an important role in establishing ECS. For example those with 
access to primary care physicians and health insurance that cover “sick” visits 
may be treated in the outpatient setting for a set time period before the clinician 
decides to admit to the hospital, while those with lack of access to the same type 
of primary care provider may be going straight to an emergency room for 
treatment and be admitted earlier. 
 There is a difference seen in the results from the methods that analyzed 
measured confounding vs the method used to analyze unmeasured confounding, 
nevertheless due to confidence intervals, these results are statistically similar. 
The confidence intervals from logistic regression and propensity score analysis 
were narrower than the confidence interval from instrumental variable analysis. 
The confidence interval from instrumental variable analysis was wider because 
the instrumental variable, ADI, was a cluster variable. Since the instrumental 
variable analysis is essentially calculating a separate model in each block group, 
similar to a multilevel model, the overall sample size can affect the smaller 
sample seen in each cluster. As the overall sample size is small there isn’t an 
equal distribution of macrolide and beta-lactam combination therapy usage and 
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ECS in each block group and the sparse data in some of the census block 
groups leads to a wider confidence interval. However, even if the sample 
analyzed was larger, there is no guarantee that the sample would be evenly 
distributed amongst block groups, and thus the confidence interval could 
continue to be wide. 
5.2 Discussion of Macrolide and Beta-Lactam Combination Therapy and 30 Day 
Mortality 
 Another objective of this analysis was to determine whether macrolide and 
beta-lactam combination therapy usage is appropriate for gold standard 
treatment in hospitalized community acquired pneumonia though assessment of 
30 day mortality. Overall, macrolide and beta-lactam therapy was not associated 
with 30 day mortality.  
 In this analysis there was no difference in the calculated OR’s from the 
methods that analyzed measured confounding (logistic regression and propensity 
score matching) and from the method used to analyze unmeasured confounding 
(instrumental variable analysis). The three odds ratios were statistically similar, in 
that each of the the confidence intervals were wide enough to include the OR’s 
from the other analytical methods. However the confidence interval for the 
instrumental variable analysis was substantially wider than that of the other two 
analytical methods. This is due to ADI being a cluster variable and the non-equal 
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distribution of macrolide and beta-lactam combination therapy usage and ECS 
amongst the census block groups, as discussed previously.  
 The non-significant OR’s of macrolide and beta-lactam combination 
therapy’s effects on 30 day mortality were similar to the results from the meta 
analyses (88, 120).  
 Asadi et al, 2012, initially found that macrolide use was associated with a 
statistically significant lower risk of mortality compared with nonmacrolide use, 
however there was a large amount of heterogeneity between the studies (88). 
When they assessed just the randomized control trials, the reduction in mortality 
was no longer apparent. The analysis also found that there was no significant 
difference in mortality comparing macrolide and beta-lactam combination therapy 
versus fluoroquinolone mono-therapy.  
 Vardakas et al, 2017, reported that mono-therapy regimens were not 
associated with higher mortality when compared with combination therapies, 
however the heterogeneity was once again high (120). They found that the 
retrospective studies reported higher mortality associated with mono-therapy, 
while both prospective studies and RCTs showed no difference in mortality. There 
was no difference in mortality between fluoroquinolone mono-therapy and b-
lactam/macrolide combination  
 The concordance between the results from the analytical methods and the 
findings from the meta analyses give credence to the understanding that there is 
no difference, with regards to 30 day mortality, between macrolide and beta-
lactam combination therapy and fluoroquinolone mono-therapy.  
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5.3 Discussion of Methods for Analyzing Confounding by Indication 
Confidence Interval difference 
 To compare the odds ratios from the various methods of addressing 
confounding by indication, the confidence intervals were used as a way to 
determine similarities. If one confidence interval included the OR’s from the other 
methods, the OR’s were determined to be similar. Although this is a useful 
method, there is no statistical significance attached to the results from this 
method. There is a lack of analytical methods to compare OR’s from various 
methods of calculation. The assumptions made in the analytical methods do not 
allow for a simple one-to-one comparison, as is seen in a Wald test.  
5.4 Discussion of Macrolide and Beta-Lactam Combination Therapy and 
Fluoroquinolone Mono-Therapy 
 Overall, there was no statistical difference between being given macrolide 
and beta-lactam combination therapy and fluoroquinolone mono-therapy with 
respect to ECS or 30 day mortality. With these results similar to those seen in 
other studies it begs the question, why is macrolide and beta-lactam combination 
therapy considered first line treatment compared to fluoroquinolone mono-
therapy? On one side there are the contraindications and complications 
associated with fluoroquinolones, which shouldn’t be ignored. However on the 
other side there is an increase in the amount of macrolide resistant S. 
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pneumoniae. It is a catch-22 cycle trying to balance side effects with drug 
resistance.  
 There needs be increased discernment in the type of antimicrobial given. 
Empiric antimicrobial therapy within the first 6 hours of admission is known to 
decrease mortality in patients with CAP. Guidelines also recommend deceleration 
of antimicrobial treatment once the pathogen is determined, however few cases 
have a defined causal pathogen. In the study population, only 16.5% of patients 
had a causal pathogen determined. 85 patients had S. pneumoniae, however 
there were 41 different pathogens, both viral and bacterial, identified.  
 Physicians should have a greater understanding of the causal pathogens 
associated with specific risk factors and locations. For example, if a patient has 
CAP and is from an area that is experiencing an outbreak, there is a greater 
likelihood of Chlamydia pneumoniae or Legionella species being the causative 
pathogen, and so caution against macrolide resistant Streptococcus pneumoniae 
may not be needed. Rapid diagnostic tests could also be beneficial as the 
pathogen could be understood at an earlier point in the course of CAP and the 




 In this study population, there is no difference in the likelihood of  
establishing ECS according to whether a patient is given macrolide and beta-
lactam combination therapy or fluoroquinolone mono-therapy. The three different 
methods used to address CBI (logistic regression, propensity score matching, 
instrumental variable analysis) showed overall similar non-significant results, 
although instrumental variable analysis, in assessing unmeasured confounding, 
found different results from the methods addressing measured confounding. 
There is no statistical difference in the likelihood of 30 day mortality between the 
antibiotic groups. Logistic regression, propensity score matching, and 
instrumental variable analysis all found similar non-significant results. Physicians 
need to have a greater understanding of the causal pathogens associated with 
specific risk factors and locations. The emergence of macrolide resistant species 
of Streptococcus pneumoniae give a reason to cautiously examine the antibiotics 
being empirically given, especially as many studies, including this one, suggest 
no association between improved clinical outcomes and antibiotic given. There is 
a need for better rapid diagnostic tests so that the causal pathogen can be 
understood at an earlier time in the clinical course of CAP.  
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6.2.2 Strengths 
 One of the main strengths of this study is that it is a unique data set, 
having almost 100% coverage of adults hospitalized with community acquired 
pneumonia in Jefferson County, Kentucky. The HAPPI study also had structural 
quality control measures (i.e. the entry system would not allow for an age of 500 
years to be input, a team of individuals went through the records and assessed 
for errors, etc.). The study is comprised of a heterogeneous population with 
regards to ethnicity and socioeconomic status. Three different models were used 
to evaluate the hypotheses of the study, which led to more informative 
conclusions. Furthermore, the exposures were verifiable due to inclusion in 
hospital records . 
6.2.3 Limitations 
 Post-hoc power analysis showed analysis was under powered, although 
when assessing the outcomes in the study using macrolide use versus non 
macrolide use (which was fully powered) similar results were seen. There was a 
potential for random error in the entry of information from hospital records, 
however this would have been non-differential and so would not have biased 
results.  There was also no accounting for potential diagnostic differences 
between the various radiologists examining the chest x-rays needed for clinical 
diagnosis of CAP. However, this would have affected those in both groups, and 
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so would have been non-differential. The results from the analysis of the effect of 
macrolide and beta-lactam therapy on early clinic stability an 30 day mortality 
may not generalizable to the other forms of pneumonia, such as HAP, HCAP, 
VAP, etc. Also, there is a question of generalizability of the results when it comes 
to other climates, as Jefferson County, Kentucky is situated in the Ohio River 
Valley which exposes the patient population to certain environmental exposures 
that may affect the pathogenicity of CAP. Intra-personal non-modifiable 
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APPENDIX I: GLOSSARY 
AAFP: American Academy of Family Physicians 
ATS: American Thoracic Society 
Beta-Lactam: Antimicrobials that are effective against gram positive bacteria and 
some gram negative bacteria. They act by inhibiting the synthesis of bacterial 
walls. 
BMI: Body Mass Index 
BTS: British Thoracic Society 
BUN: Blood Urea Nitrogen 
CAP: Community Acquired Pneumonia 
CBI: Confounding by indication 
CHF: Congestive heart failure 
Confounding: When a variable has been found to influence both the 
independent variable (e.g. an antibiotic treatment) and the dependent variable 
(e.g. a clinical outcome). 
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Confounding by Indication (CBI): A type of confounding that occurs when a 
treatment (the primary predictor variable) is selected due to a specific 
characteristic (e.g. history of a particular disease, provider medication 
preference) and this characteristic also affects the risk of the outcome variable. 
COPD: Chronic obstructive pulmonary disease 
Community Acquired Pneumonia (CAP): Characterized by acute symptoms 
such as dyspnea, cough, fever, or chest pain, it is diagnosed by the presence of 
pulmonary infiltrate seen on radiography 
CURB-65: Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years 
of age and older; Used to predict the need for hospitalization for a patient who 
has community acquired pneumonia 
CVD: Cerebrovascular disease 
DBP: Diastolic blood pressure 
ECS: Early Clinical Stability 
Early Clinical Stability (ECS): The following criteria are met within 3 days of 
admission; improved symptoms of pneumonia (cough and shortness of breath), 
lack of fever for at least eight hours, improving leukocytosis (decreased at least 
10% from the previous day), and ability to take oral medications 
FDA: Federal Drug Administration 
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Fluoroquinolone: Antimicrobials that work best against aerobic gram-negative 
bacilli. They are direct inhibitors of bacterial DNA synthesis and bind to the 
complex of specific enzymes within DNA and thus inhibit progress of the DNA 
replication leading to bacterial DNA and bacterial cell death. 
HAP: Hospital-acquired pneumonia 
HAPPI: Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study 
HCAP: Healthcare associated pneumonia 
HIV: Human immunodeficiency virus 
HR: Heart rate 
ICU: Intensive care unit 
IDSA: Infectious Diseases Society of America 
Instrument: Seemingly random variable that is strongly associated with the 
predictor variable under study but not associated with the outcome. 
Instrumental Variable Analysis: Makes use of an IV or an instrument to control 
for unmeasured variation between confounders. 
IV: Intravenous  
Logistic Regression: A statistical method for analyzing a dataset in which there 
are one or more independent variables that determine an outcome. The outcome 
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is measured with a dichotomous variable (in which there are only two possible 
outcomes) 
Macrolide: Antimicrobials that are used to treat gram positive bacteria, such as 
S. pneumoniae, and some gram negative bacteria like H. influenzae. Macrolides 
inhibit protein synthesis in bacteria by binding to the 50S ribosomal subunit and 
preventing polypeptide elongation and thus protein synthesis. 
Pneumonia Severity Index (PSI): Used to predict the need for hospitalization for 
a patient who has community acquired pneumonia 
Propensity Score: Probability of treatment assignment conditional on observed 
baseline characteristics.  
PSI: Pneumonia severity index 
SBP: Systolic blood pressure 
Severe: This variable was created from a score based on the severity criteria 
recommended by the ATS/IDSA. 
RR: Respiratory rate 
VAP: Ventilator-associated pneumonia 
30 day mortality: All cause-mortality within 30 days of hospital discharge. 
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APPENDIX II: ADDITIONAL TABLES 
ECS: Multivariable Logistic Regression, Data-based Method for Assessment 
Variable Validitya Precisionb Percent Change
Full Model 
 
Macrolide and Beta-Lactam + 
Covariates (dem_age + lab_glucose + 
smoking.current + hx_ivdruguse + 
hx_cirrhosis + lab_hematocrit + 
risk_nursinghome + hx_chf + hx_copd 
+ exam_hr + severe) -0.0951 0.0788
remove age          -0.0951 0.0787 0.01%
remove glucose      -0.0964 0.0787 1.31%
remove smoking -0.0964 0.0787 1.32%
remove IV drug use   -0.0960 0.0788 0.89%
remove cirrhosis     -0.0964 0.0787 1.34%
remove hematocrit   -0.0901 0.0786 5.30%
remove residence in nursing home -0.0817 0.0784 14.06% +
remove CHF        -0.0914 0.0787 3.92% **
remove COPD          -0.0811 0.0785 14.69% **+
remove HR          -0.1072 0.0785 12.74% **+
remove severe           -0.1189 0.0782 24.95% **+
a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable Validitya Precisionb Percent Change
Remove dem_age 
 
Macrolide and Beta-Lactam + 
Covariates (lab_glucose + 
smoking.current + hx_ivdruguse + 
hx_cirrhosis + lab_hematocrit + 
risk_nursinghome + hx_chf + hx_copd 
+ exam_hr + severe) -0.0951 0.0787
remove glucose      -0.0964 0.0786 1.33%
remove smoking -0.0969 0.0787 1.88%
remove IV drug use   -0.0961 0.0787 1.06%
remove cirrhosis     -0.0964 0.0787 1.34%
remove hematocrit   -0.0901 0.0786 5.24%
remove residence in nursing home -0.0812 0.0783 14.58% +
remove CHF        -0.0907 0.0786 4.62% **
remove COPD          -0.0790 0.0785 16.90% **+
remove HR          -0.1098 0.0784 15.43% **+
remove severe           -0.1176 0.0782 23.67% **+
Remove dem_age + lab_glucose 
 
Macrolide and Beta-Lactam + 
Covariates (smoking.current + 
hx_ivdruguse + hx_cirrhosis + 
lab_hematocrit + risk_nursinghome + 
hx_chf + hx_copd + exam_hr + 
severe) -0.0964 0.0786
remove smoking -0.0982 0.0786 1.92%
remove IV drug use   -0.0973 0.0786 0.95%
remove cirrhosis     -0.0977 0.0786 1.34%
remove hematocrit   -0.0914 0.0785 5.18%
a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable Validitya Precisionb Percent Change
remove residence in nursing home -0.0825 0.0782 14.41% +
remove CHF        -0.0929 0.0785 3.56% **
remove COPD          -0.0813 0.0783 15.68% **+
remove HR          -0.1127 0.0783 16.99% **+
remove severe           -0.1206 0.0781 25.20% **+
Remove dem_age + lab_glucose + 
smoking.current 
 
Macrolide and Beta-Lactam + 
Covariates (hx_ivdruguse + 
hx_cirrhosis + lab_hematocrit + 
risk_nursinghome + hx_chf + hx_copd 
+ exam_hr + severe) -0.0982 0.0786
remove IV drug use   -0.0996 0.0785 1.42%
remove cirrhosis     -0.0996 0.0785 1.39%
remove hematocrit   -0.0933 0.0784 5.02%
remove residence in nursing home -0.0842 0.0781 14.32% +
remove CHF        -0.0940 0.0784 4.27% **
remove COPD          -0.0849 0.0783 13.51% **+
remove HR          -0.1159 0.0782 18.00% **+
remove severe           -0.1214 0.0780 23.58% **+
a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable Validitya Precisionb Percent Change
Remove dem_age + lab_glucose + 
smoking.current + hx_ivdruguse 
 
Macrolide and Beta-Lactam + 
Covariates (hx_cirrhosis + 
lab_hematocrit + risk_nursinghome + 
hx_chf + hx_copd + exam_hr + 
severe) -0.0996 0.0785
remove cirrhosis     -0.1011 0.0785 1.54%
remove hematocrit   -0.0947 0.0784 4.96%
remove residence in nursing home -0.0855 0.0781 14.18% +
remove CHF        -0.0953 0.0784 4.35% **
remove COPD          -0.0860 0.0782 13.64% **+
remove HR          -0.1183 0.0782 18.81% **+
remove severe           -0.1234 0.0780 23.85% **+
Remove dem_age + lab_glucose + 
smoking.current + hx_ivdruguse + 
hx_cirrhosis 
 
Macrolide and Beta-Lactam + 
Covariates (lab_hematocrit + 
risk_nursinghome + hx_chf + hx_copd 
+ exam_hr + severe) -0.1011 0.0785
remove hematocrit   -0.0962 0.0783 4.87%
remove residence in nursing home -0.0871 0.0780 13.93% +
remove CHF        -0.0968 0.0784 4.32% **
remove COPD          -0.0876 0.0782 13.41% **+
remove HR          -0.1199 0.0781 18.59% **+
remove severe           -0.1251 0.0779 23.71% **+
a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable Validitya Precisionb Percent Change
Remove dem_age + lab_glucose + 
smoking.current + hx_ivdruguse + 
hx_cirrhosis + lab_hematocrit  
 
Macrolide and Beta-Lactam + 
Covariates (risk_nursinghome + 
hx_chf + hx_copd + exam_hr + 
severe) -0.0962 0.0783
remove residence in nursing home -0.0830 0.0779 13.73% **+
remove CHF        -0.0925 0.0782 3.85% **
remove COPD          -0.0807 0.0780 16.16% **+
remove HR          -0.1141 0.0780 18.53% **+
remove severe           -0.1235 0.0778 28.32% +
a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment 
Variable Validitya Precisionb Percent Change
Full Model 
 
Macrolide and Beta-Lactam + 
Covariates (smoking.current + 
hx_copd +  hx_chf + 
risk_nursinghome + hx_cirrhosis + 
lab_glucose + hx_ivdruguse + 
lab_hematocrit + exam_hr + severe + 
dem_age) -0.0734 0.7426
remove smoking -0.0741 0.1495 0.97%
remove COPD          -0.0767 0.1494 4.59%
a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment 
(continued)
Variable Validitya Precisionb Percent Change
remove CHF         -0.0769 0.1494 4.78%
remove residence in nursing home -0.0962 0.1483 31.14% +
remove cirrhosis     -0.0679 0.1493 7.44%
remove glucose      -0.0581 0.1491 20.86% +
remove IV drug use     -0.0668 0.1494 8.91% **
remove hematocrit   -0.0361 0.1487 50.83% **+
remove HR          -0.0500 0.1484 31.89% **+
remove severe           -0.0219 0.1480 70.18% **+
remove age          -0.0822 0.0822 12.11% **+
Remove smoking.current 
 
Macrolide and Beta-Lactam + 
Covariates (hx_copd +  hx_chf + 
risk_nursinghome + hx_cirrhosis + 
lab_glucose + hx_ivdruguse + 
lab_hematocrit + exam_hr + severe + 
dem_age) -0.0741 0.1495
remove COPD          -0.0769 0.1494 3.83%
remove CHF         -0.0779 0.1494 5.24%
remove residence in nursing home -0.0973 0.1482 31.35% +
remove cirrhosis     -0.0686 0.1493 7.43%
remove glucose      -0.0588 0.1491 20.60% +
remove IV drug use     -0.0671 0.1493 9.38% **
remove hematocrit   -0.0371 0.1486 49.93% **+
remove HR          -0.0505 0.1484 31.86% **+
a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment 
(continued)
Variable Validitya Precisionb Percent Change
remove severe           -0.0228 0.1480 69.25% **+
remove age          -0.0921 0.1476 24.34% **+
Remove smoking.current + hx_copd 
 
Macrolide and Beta-Lactam + 
Covariates (hx_chf + 
risk_nursinghome + hx_cirrhosis + 
lab_glucose + hx_ivdruguse + 
lab_hematocrit + exam_hr + severe + 
dem_age) -0.0769 0.1494
remove CHF         -0.0823 0.1492 6.99%
remove residence in nursing home -0.1001 0.1481 30.22% +
remove cirrhosis     -0.0713 0.1492 7.23%
remove glucose      -0.0622 0.1490 19.11% +
remove IV drug use     -0.0695 0.1492 9.64% **
remove hematocrit   -0.0375 0.1484 51.27% **+
remove HR          -0.0550 0.1483 28.43% **+
remove severe           -0.0265 0.1479 65.55% **+
remove age          -0.0968 0.1474 25.88% **+
Remove smoking.current + hx_copd + 
hx_chf  
 
Macrolide and Beta-Lactam + 
Covariates (risk_nursinghome + 
hx_cirrhosis + lab_glucose + 
hx_ivdruguse + lab_hematocrit + 
exam_hr + severe + dem_age) -0.0823 0.1492
remove residence in nursing home -0.1058 0.1479 28.64% +
remove cirrhosis     -0.0764 0.1490 7.12%
a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment 
(continued)
Variable Validitya Precisionb Percent Change
remove glucose      -0.0670 0.1489 18.51% +
remove IV drug use     -0.0748 0.1490 9.14% **
remove hematocrit   -0.0421 0.1483 48.87% **+
remove HR          -0.0602 0.1482 26.82% **+
remove severe           -0.0330 0.1477 59.83% **+
remove age          -0.1089 0.1471 32.42% **+
Remove smoking.current + hx_copd + 
hx_chf + hx_cirrhosis 
 
Macrolide and Beta-Lactam + 
Covariates (risk_nursinghome + 
lab_glucose + hx_ivdruguse + 
lab_hematocrit + exam_hr + severe + 
dem_age) -0.0764 0.1490
remove residence in nursing home -0.0996 0.1477 30.36% +
remove glucose      -0.0614 0.1487 19.70% +
remove IV drug use     -0.0686 0.1489 10.23% **+
remove hematocrit   -0.0375 0.1481 50.96% **+
remove HR          -0.0543 0.1480 28.90% **+
remove severe           -0.0258 0.1475 66.19% **+
remove age          -0.1039 0.1469 35.94% **+
a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality 
b, Standard error 
+, changed the beta coefficient of macrolide + beta-lactam more than 10% 
**, statistically significant in full model so will be included in final model
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